ProShares Ultra Bitcoin ETF vs GSK plc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.16, while GSK plc trades at $50.42 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while ProShares Ultra Bitcoin ETF pays none, and GSK plc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | GSK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $61.18 |
52-Week Low | $8.12 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.145, down 1.98% today, with a bearish technical outlook as moving averages signal strong selling pressure. The stock has shown consistent dividend payments, with the latest being $0.02 per share. Recent news highlights concerns over its leveraged structure and volatility decay, impacting investor confidence.
The outlook remains cautious due to weak technical signals and negative sentiment. Risks include high volatility and underperformance in non-bull markets. Analyst consensus leans bearish, with limited fundamental data available to support a positive near-term view.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →